A critical role for the programmed death ligand 1 in fetomaternal tolerance

被引:336
|
作者
Guleria, I [1 ]
Khosroshahi, A
Ansari, MJ
Habicht, A
Azuma, M
Yagita, H
Noelle, RJ
Sayegh, MH
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA
[4] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo 1138549, Japan
[5] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan
[6] Dartmouth Coll, Hanover, NH 03755 USA
[7] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA
[8] Med Coll Georgia, Dept Med, Inst Mol Med & Genet, Program Mol Immunol, Augusta, GA 30912 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2005年 / 202卷 / 02期
关键词
D O I
10.1084/jem.20050019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fetal survival during gestation implies that tolerance mechanisms suppress the maternal immune response to paternally inherited alloantigens. Here we show that the inhibitory T cell costimulatory molecule, programmed death ligand 1 (PDL1), has an important role in conferring fetomaternal tolerance in an allogeneic pregnancy model. Blockade of PDL1 signaling during murine pregnancy resulted in increased rejection rates of allogeneic concepti but not syngeneic concepti. Fetal rejection was T cell - but not B cell - dependent because PDL1-specific antibody treatment caused fetal rejection in B cell - deficient but not in RAG-1-deficient females. Blockade of PDL1 also resulted in a significant increase in the frequency of IFN-gamma-producing lymphocytes in response to alloantigen in an ELISPOT assay and higher IFN-gamma levels in placental homogenates by ELISA. Finally, PDL1-deficient females exhibited decreased allogeneic fetal survival rates as compared with littermate and heterozygote controls and showed evidence of expansion of T helper type 1 immune responses in vivo. These results provide the first evidence that PDL1 is involved in fetomaternal tolerance.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 50 条
  • [21] The predictive role of soluble programmed death ligand 1 in digestive system cancers
    Ruan, Jian
    Zhao, Zhihong
    Qian, Yuting
    Xu, Ruilian
    Liao, Guixiang
    Kong, Feng-Ming
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [22] Programmed death ligand 1 regulation in ccRCC
    Louise Stone
    Nature Reviews Urology, 2016, 13 (2) : 65 - 65
  • [23] A pivotal role for galectin-1 in fetomaternal tolerance
    Sandra M Blois
    Juan M Ilarregui
    Mareike Tometten
    Mariana Garcia
    Arif S Orsal
    Rosalia Cordo-Russo
    Marta A Toscano
    Germán A Bianco
    Peter Kobelt
    Bori Handjiski
    Irene Tirado
    Udo R Markert
    Burghard F Klapp
    Francoise Poirier
    Julia Szekeres-Bartho
    Gabriel A Rabinovich
    Petra C Arck
    Nature Medicine, 2007, 13 : 1450 - 1457
  • [24] Role Played by the Programmed Death-1-Programmed Death Ligand Pathway during Innate Immunity against Mycobacterium tuberculosis
    Alvarez, Ivana B.
    Pasquinelli, Virginia
    Jurado, Javier O.
    Abbate, Eduardo
    Musella, Rosa M.
    de la Barrera, Silvia S.
    Garcia, Veronica E.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (04): : 524 - 532
  • [25] Tumor Progression by Immune Evasion in Melanoma Role of the Programmed Cell Death-1/Programmed Cell Death-1 Ligand 1 Interaction
    Kashani-Sabet, Mohammed
    CANCER, 2010, 116 (07) : 1623 - 1625
  • [26] Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
    Yang, Min-Wei
    Fu, Xue-Liang
    Jiang, Yong-Sheng
    Chen, Xiao-Jing
    Tao, Ling-Ye
    Yang, Jian-Yu
    Huo, Yan-Miao
    Liu, Wei
    Zhang, Jun-Feng
    Liu, Pei-Feng
    Liu, Qiang
    Hua, Rong
    Zhang, Zhi-Gang
    Sun, Yong-Wei
    Liu, De-Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (14) : 1684 - 1696
  • [27] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [28] Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma
    Tamura, Akihiro
    Yoshida, Makiko
    Yamamoto, Nobuyuki
    Nino, Nanako
    Nakatani, Naoko
    Ichikawa, Takayuki
    Nakamura, Sayaka
    Saito, Atsuro
    Kozaki, Aiko
    Kishimoto, Kenji
    Ishida, Toshiaki
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    BLOOD, 2018, 132
  • [29] Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
    Min-Wei Yang
    Xue-Liang Fu
    Yong-Sheng Jiang
    Xiao-Jing Chen
    Ling-Ye Tao
    Jian-Yu Yang
    Yan-Miao Huo
    Wei Liu
    Jun-Feng Zhang
    Pei-Feng Liu
    Qiang Liu
    Rong Hua
    Zhi-Gang Zhang
    Yong-Wei Sun
    De-Jun Liu
    World Journal of Gastroenterology, 2019, 25 (14) : 1684 - 1696
  • [30] Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
    Nada, Hanan R.
    Mourad, Ahmed
    Rashed, Laila A.
    El-Hanafy, Ghada M.
    Abdallah, Nermeen M. A.
    Abdelhady, Mohamed M.
    JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY, 2025, 22 (01): : 79 - 87